Search

Your search keyword '"G, Gaedicke"' showing total 159 results

Search Constraints

Start Over You searched for: Author "G, Gaedicke" Remove constraint Author: "G, Gaedicke" Database MEDLINE Remove constraint Database: MEDLINE
159 results on '"G, Gaedicke"'

Search Results

1. Call for a European Paediatric Association/Union of National European Paediatric Societies and Associations Survey on National Child Health Care Services for European Children with Malignancies.

2. The importance of the patient voice in vaccination and vaccine safety-are we listening?

Catalog

Books, media, physical & digital resources

3. Teaching vaccine safety communication to medical students and health professionals.

4. A design thinking approach to effective vaccine safety communication.

5. Awareness and utilization of reporting pathways for adverse events following immunization: online survey among pediatricians in Russia and Germany.

6. Quality of life in childhood immune thrombocytopenia: international validation of the kids' ITP tools.

7. Two patterns of thrombopoietin signaling suggest no coupling between platelet production and thrombopoietin reactivity in thrombocytopenia-absent radii syndrome.

9. Immature platelet count: a simple parameter for distinguishing thrombocytopenia in pediatric acute lymphocytic leukemia from immune thrombocytopenia.

10. Continuous veno-venous single-pass albumin hemodiafiltration in children with acute liver failure.

11. Systematic amino acid substitutions improved efficiency of GD2-peptide mimotope vaccination against neuroblastoma.

12. Eradication of CD19+ leukemia by targeted calicheamicin θ.

13. Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma.

14. Survivin minigene DNA vaccination is effective against neuroblastoma.

15. A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity.

16. Nutrient mixture including vitamin C, L-lysine, L-proline, and epigallocatechin is ineffective against tumor growth and metastasis in a syngeneic neuroblastoma model.

17. Primary ciliary dyskinesia associated with normal axoneme ultrastructure is caused by DNAH11 mutations.

18. Atypical tetanus in a completely immunized 14-year-old boy.

19. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.

20. Pulmonary hypertension in a case of Hb-Mainz hemolytic anemia.

21. Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases.

22. Some unsettled questions in childhood thrombocytopenia caused by immunologic platelet destruction (acute and chronic ITP).

23. Simultaneous, phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody enhances antiangiogenic effects in vivo.

24. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.

25. Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted IL-2.

26. DNA minigene vaccination for adjuvant neuroblastoma therapy.

27. Pulmonary symptoms in Kawasaki disease.

28. Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children.

30. Response to intravenous immunoglobulin G in an infant with immunoglobulin A-associated autoimmune haemolytic anaemia.

31. Cardiac rescue with enoximone in volume and catecholamine refractory septic shock.

32. Viral agents of acute gastroenteritis in German children: prevalence and molecular diversity.

33. Rationally designed hydrolytically activated etoposide prodrugs, a novel strategy for the treatment of neuroblastoma.

34. Vaccination with minigenes encoding for novel 'self' antigens are effective in DNA-vaccination against neuroblastoma.

35. Neuroblastoma directed therapy by a rational prodrug design of etoposide as a substrate for tyrosine hydroxylase.

36. Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug-resistant T-cell leukemia.

37. A novel 2'-(N-methylpyridinium acetate) prodrug of paclitaxel induces superior antitumor responses in preclinical cancer models.

38. Angiogenesis, views and news. The 93rd annual meeting of the American Association for Cancer Research. April 6-10 2002, Moscone Convention Center, San Francisco, USA.

39. Synthesis, hydrolytic activation and cytotoxicity of etoposide prodrugs.

40. IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy.

41. Familial dysautonomia: a diagnostic dilemma. chronic lung disease with signs of an autoimmune disease.

42. Synthesis and preclinical characterization of a paclitaxel prodrug with improved antitumor activity and water solubility.

43. The B cell superantigen-like interaction of intravenous immunoglobin (IVIG) with Fab fragments of V(H) 3-23 and 3-30/3-30.5 germline gene origin cloned from a patient with Kawasaki disease is enhanced after IVIG therapy.

44. Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma.

45. Restricted VH3 gene usage in phage-displayed Fab that are selected by intravenous immunoglobulin.

46. Targeted therapy of experimental renal cell carcinoma with a novel conjugate of monoclonal antibody 138H11 and calicheamicin thetaI1.

47. IVIG-bound IgG and IgM cloned by phage display from a healthy individual reveal the same restricted germ-line gene origin as in autoimmune thrombocytopenia.

48. Dominant beta-thalassaemia: a highly unstable haemoglobin is caused by a novel 6 bp deletion of the beta-globin gene.

49. Hemothorax under thrombolytic therapy with recombinant tissue: plasminogen activator (rt-PA) in a 16-year-old girl.

50. Low-dose spiral CT: applicability to paediatric chest imaging.